Cell Captives and Protected Cell Companies: A Feasibility Read for Indian Corporates in 2026

A protected cell company (PCC) is a single legal entity divided into a non-cellular core and a number of legally segregated cells. The core is owned and capitalised by the cell facility's promoter (typically an insurer, reinsurer or specialist manager), and each cell is sponsored by a separate participant, usually a corporate that wants to self-insure part of its risk. The defining feature is statutory ring-fencing: the assets of one cell are protected from the liabilities of another cell and of the core, so a participant's cell is insulated from the losses, insolvency or disputes of every other participant sharing the same PCC. A cell captive is a cell used by a corporate to retain and finance its own risk, the same economic purpose as a standalone captive, but housed inside shared infrastructure rather than a wholly-owned insurance company.

The contrast with a standalone captive is the heart of the feasibility question. A standalone captive is a free-standing licensed insurer or reinsurer that the parent owns outright. The parent funds the minimum capital, appoints the board, commissions the actuarial and audit functions, files its own regulatory returns and bears the full fixed cost of running a regulated insurance entity. In the GIFT City IFSC, an Indian corporate setting up a standalone captive faces a minimum capital requirement in the order of USD 1.5 million (around INR 12 to 13 crore) plus the recurring cost of management, actuarial certification, audit and compliance, which can run to several crore a year before a single claim is paid.

A cell removes most of that fixed cost. The participant does not own a licensed insurer; it sponsors a cell within the promoter's already-licensed PCC, contributes the capital and collateral its own cell's risk requires, and shares the core's governance, actuarial, audit and compliance machinery. The promoter runs the entity; the participant runs its cell's underwriting and funding decisions. The economic substance, retaining risk that the commercial market prices expensively and recapturing the underwriting margin and investment income, is the same as a standalone captive. The structure, cost and speed of entry are very different.

The feasibility decision turns on premium volume, the durability of the captive intent, and the appetite for governance overhead. A cell and a standalone captive sit at different points on the cost curve, and the crossover is what a corporate has to estimate. It is worth naming the three rungs on the ladder before sizing them: a rent-a-captive account (where the participant uses the promoter's facility on a contractual basis but without a dedicated, legally protected cell, so its funds are commingled with the promoter's other rent-a-captive accounts and protected only by contract), a protected or incorporated cell (where statutory ring-fencing legally segregates the participant's cell from every other), and a standalone captive (a wholly-owned licensed insurer). The cell sits deliberately between rent-a-captive and standalone: it adds statutory segregation that a bare rent-a-captive lacks, without the full fixed cost a standalone carries. A mid-market Indian corporate that is nervous about commingling but not yet ready to own an insurer is exactly the buyer the cell was designed for.

Where a cell wins

A cell wins where the retained premium is modest, where the corporate is testing the captive idea before committing, or where it wants statutory segregation without the fixed cost of a regulated entity. Because the participant shares the core's capital base and the promoter's management, actuarial, audit and compliance functions, the recurring cost of a cell is a fraction of a standalone captive's. A corporate retaining, say, INR 5 to 25 crore of annual premium across property deductible buy-downs, employee benefits or a slice of liability often cannot justify several crore of standalone running cost against that premium, and the cell brings the fixed overhead down to a level the retained margin can carry. Set-up is also faster: sponsoring a cell in an established PCC can take weeks rather than the months a fresh licence application consumes, and the capital the participant must contribute is sized to its own cell's risk rather than a full insurer's minimum.

Where a standalone captive wins

A standalone captive wins at scale and at permanence. Once the retained premium is large (commonly INR 50 crore and above of annual ceded premium), the fixed cost of running a dedicated insurer is small relative to the book, and the standalone form gives the parent total control: its own board, its own investment policy, its own reinsurance buying, no sharing of the core's policies or the promoter's commercial priorities, and a balance sheet it owns rather than rents. A standalone captive can also write a wider range of risks, build retained earnings over years, and become a strategic risk-financing vehicle in its own right. A large conglomerate that has decided captive insurance is a permanent part of its risk architecture usually ends up standalone.

Reading the crossover

The practical reading for a mid-size corporate is to treat the cell as the entry route and the standalone captive as a possible destination. A cell lets the corporate prove the captive economics, build the data and the discipline, and establish the retained-risk track record on a fraction of the commitment. If the retained book grows and the intent hardens, the corporate can graduate to a standalone captive later, carrying forward the experience the cell produced. Treating the two as a sequence rather than an either-or is usually the right frame for a corporate that is not yet certain captive insurance is permanent for it. The related decision for a conglomerate that is certain is set out in the captive business case for Indian conglomerates.

What makes the cell route a live 2026 question for Indian corporates is that GIFT City has begun to host the cell form itself, not merely whole captives. The International Financial Services Centres Authority (IFSCA) supervises insurance and reinsurance entities in the IFSC as IFSC Insurance Offices (IIOs), and alongside its single-parent captive regime it has been building rules under which a promoter can operate a protected or incorporated cell company as the core and admit corporate participants as segregated cells. That is the piece that matters here: a sponsor no longer has to charter a full IIO of its own to gain a domestically located, IFSCA-supervised home for retained risk; it can take a compartment inside a promoter's licensed cell facility.

A prospective cell sponsor should test the GIFT City cell facility on three points specific to the cell form rather than to captives generally. First, enforceable segregation: confirm that the statutory ring-fence between cells, and between each cell and the core, is recognised and would hold in an Indian-seated dispute, because the cell's entire protection rests on it. Second, the cell-level entry threshold: the minimum contribution and the solvency expected of an individual cell, which are a fraction of a standalone IIO's full minimum capital and are what make the compartment economic at modest premium. Third, the core's standing: the promoter operating the core must itself be a licensed, adequately capitalised IIO, since a participant relies on the core's solvency for the shared functions. For an India-centric group, a GIFT City compartment pairs the protected-cell mechanics that Guernsey, Malta and Mauritius have run for decades with an onshore-adjacent, rupee-friendly, IFSCA-supervised setting.

Comparing a GIFT City compartment with an offshore cell

A GIFT City cell does not automatically dominate an offshore one. The mature cell jurisdictions have long-tested segregation case law, deep cell-manager and captive-manager markets, and recognition that international retrocessionaires understand instinctively, which counts when the cell needs to retrocede or slot into a global programme. The GIFT City compartment counters with domestic location, alignment with Indian expectations, an emerging IFSCA cell ecosystem, and cleaner optics for an Indian board. A sponsor weighing the two should compare cell-manager depth, segregation-law maturity, retrocession access and its own international footprint, the comparison taken further in captive formation across Bermuda, Singapore and GIFT City.

A cell, like any captive, rarely insures the sponsor's Indian risk directly. Property, liability, marine and engineering risks situated in India must be written by an IRDAI-admitted insurer, so the cell participates one step back, as the reinsurer of an admitted fronting insurer. The fronting insurer issues the policy the sponsor needs, stands as the insurer of record before the policyholder, and cedes an agreed quota share or surplus share down to the cell. The compartment thus sits behind the sponsor's own risk as a reinsurance counterparty, recapturing the ceded margin, while the admitted paper carries the regulatory face of the cover.

Fronting is not free, and the fronting economics often decide a cell's feasibility. The fronting insurer charges a fronting fee (a ceding charge) of broadly 3 to 10 percent of ceded premium, varying with the line, the limit and the perceived recoverability of the cell as a reinsurer, to compensate for the solvency capital it must hold against the gross policy, the issuance and servicing work, and the reinsurance credit risk that the cell might not pay its share. Because a cell's balance sheet is small and ring-fenced rather than a full insurer's, fronting insurers scrutinise cell recoverability more closely than they would a standalone captive of scale, which can push a cell's ceding charge to the upper end of that band. The detailed mechanics are in fronting arrangements for captives in India.

Collateralising the cell's reinsurance obligation

The fronting insurer remains liable to the policyholder for the gross claim while depending on the cell to reimburse the ceded layer, so it demands collateral against the cell's reinsurance obligation. For a cell the collateral is usually a letter of credit drawn on the sponsor's bank, a reinsurance trust, or funds-withheld, sized to the cell's expected liabilities plus an adverse-development margin. The collateral attaches to the cell, not to the core, which is one practical consequence of segregation: the promoter cannot pledge one participant's cell assets to support another's fronting, and the fronting insurer must look only to the sponsoring cell's collateral for that cell's risk. The letter-of-credit fee and the opportunity cost of the pledged capital are a real line in the cell's all-in cost, and they do not shrink simply because the entity overhead is shared.

Reading the cell's all-in cost

A candid cell feasibility model sums the cell's contributed capital, the collateral carrying cost, the ceding charge, the cell's pro-rata slice of the core's management, actuarial, audit and compliance budget, and any retrocession the cell buys above its own net retention, then sets the total against the commercial premium avoided and the underwriting and investment margin recaptured inside the compartment. Sharing the core slashes the entity-overhead line that dominates a standalone captive's cost, which is the whole point of renting a cell, but the ceding charge and the cell collateral are risk costs rather than structure costs, so they sit on a cell exactly as they sit on a standalone. A cell lowers the premium volume at which captive economics start to work; it does not erase the price of getting Indian risk to the compartment.

Renting a cell is cheaper than owning a captive precisely because the participant shares the core, and the governance and accounting realities of that sharing are where the model needs care. The segregation that protects a cell is statutory, but it has to be respected operationally, and the participant has to understand what it controls and what it does not.

What the participant controls and what the core controls

Within its cell, the participant drives the underwriting decisions: what risk the cell reinsures, at what retention, with what reinsurance above it, and how the cell's funds are managed within the policy the core sets. What the participant does not control is the entity. The PCC's board, its overall investment policy, its choice of auditor and actuary, its compliance posture and its relationships with regulators and fronting insurers are the promoter's. A participant that wants total control over those is in the wrong structure and should be looking at a standalone captive. A participant that is comfortable letting a competent promoter run the entity while it runs its cell gets the cost benefit the model exists to provide. Choosing the promoter is therefore the most consequential decision in the cell route, because the participant is relying on the promoter's solvency, competence and good faith for the parts of the operation it has handed over.

The accounting and ring-fencing realities

Each cell maintains its own accounts, its own assets and liabilities, and its own result, and the PCC reports cell-by-cell so that the segregation is visible and auditable. The participant has to account for its cell in its own group financials, recognising the captive's results and the value of its participation, and the captive's existence brings transfer-pricing, related-party and tax considerations that need professional advice, because the premium the corporate pays into its own cell has to be arm's-length and the arrangement has to satisfy the tax authorities that it is genuine risk transfer and not a deduction-engineering exercise.

The ring-fencing, though statutory, is only as strong as the jurisdiction's law and the courts that would enforce it, which is one more reason the domicile and the legal form matter. A well-established PCC jurisdiction with tested segregation law and a competent regulator gives the participant confidence that its cell really is insulated from the others. A new or untested regime carries more uncertainty about how the segregation would hold if a co-participant's cell failed badly, which is a live consideration as the GIFT City PCC ecosystem matures.

The cell-versus-standalone decision is a structured comparison, and a corporate that works through it in order reaches a defensible answer rather than a fashionable one. The starting point is not the structure but the risk: which exposures the corporate is paying the commercial market a margin to carry that it could retain, fund and manage itself, and whether the retained premium and the durability of the intent justify a captive at all.

The decision sequence runs roughly as follows.

1. Quantify the retained book. Identify the risks the corporate would feed a captive (property deductible layers, own-damage, a liability slice, employee benefits) and the annual premium and expected losses involved. This sizes the captive and sets the premium against which every fixed and variable cost will be weighed.
2. Test the durability of the intent. A captive is a multi-year commitment; a corporate dabbling for one favourable market cycle should not build a standalone insurer. The more tentative the intent, the more a cell's lower commitment and faster exit favour it.
3. Model the all-in cost of each form. Build the cell cost (contributed capital, collateral, fronting fee, share of core overhead, reinsurance) and the standalone cost (full capital, full management, actuarial, audit, compliance, fronting, collateral, reinsurance) and compare both against the commercial premium and the margin recaptured.
4. Choose the domicile and, for a cell, the promoter. Compare GIFT City against the established offshore PCC domiciles on cost, service-provider depth, reinsurance access and the maturity of the segregation regime, and for a cell, diligence the specific promoter and the co-participants.
5. Plan the fronting and collateral. Line up the admitted fronting insurer, negotiate the fronting fee, and arrange the collateral, because these determine whether the retained margin survives the cost of getting the Indian risk to the cell.
6. Decide cell now, standalone later, or standalone now. For most mid-size corporates the answer is a cell as the entry vehicle with a standalone captive as a possible later destination; for a large group certain of permanence, a standalone captive from the start.

Working the decision well depends on understanding the risks the captive will retain at the level of the actual policy wordings: the triggers, grants, sub-limits and exclusions that determine what the captive is really taking on when it reinsures a fronted policy. A captive that misreads the wording of the risk it retains can recapture a margin it did not understand and find itself funding a loss it did not price. Sarvada gives commercial insurance brokers and corporate risk teams structured, searchable access to insurer policy wordings, so the retention and fronting decisions behind a cell or standalone captive rest on a precise reading of the cover, not an approximation. Request Access to ground your captive feasibility work in the real wordings of the risks you intend to retain.